You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

CLINICAL TRIALS PROFILE FOR LINDANE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for lindane

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00604084 ↗ Veron Scabies Education and Eradication Program Completed Edward Via Virginia College of Osteopathic Medicine N/A 2007-05-01 The purpose of this project is to develop a community scabies eradication and education program for the highly endemic areas surrounding the Veron community on the eastern tip of the Dominican Republic. It proposes the use of oral Ivermectin as a replacement for topical Lindane--a readily available medical formulation, pesticide, and environmental toxin that is reported to be banned in the Dominican Republic as well as over 80 other countries throughout the world.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 1 of 1 entries

Clinical Trial Conditions for lindane

Condition Name

10-0.100.10.20.30.40.50.60.70.80.911.1Scabies[disabled in preview]
Condition Name for lindane
Intervention Trials
Scabies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

10-0.100.10.20.30.40.50.60.70.80.911.1Scabies[disabled in preview]
Condition MeSH for lindane
Intervention Trials
Scabies 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for lindane

Trials by Country

+
Trials by Country for lindane
Location Trials
Dominican Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for lindane

Clinical Trial Phase

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1N/A[disabled in preview]
Clinical Trial Phase for lindane
Clinical Trial Phase Trials
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Completed[disabled in preview]
Clinical Trial Status for lindane
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for lindane

Sponsor Name

trials000001111111Edward Via Virginia College of Osteopathic Medicine[disabled in preview]
Sponsor Name for lindane
Sponsor Trials
Edward Via Virginia College of Osteopathic Medicine 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

100.0%0-0.100.10.20.30.40.50.60.70.80.911.1Other[disabled in preview]
Sponsor Type for lindane
Sponsor Trials
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Lindane Market Analysis and Financial Projection

Clinical Trials, Market Analysis, and Projections for Lindane

Introduction to Lindane

Lindane, also known as gamma-hexachlorocyclohexane (γ-HCH), is a pesticide and pharmaceutical agent used primarily for the treatment of lice and scabies. Here, we will delve into the current state of clinical trials involving lindane, its market analysis, and future projections.

Clinical Trials Overview

Clinical trials involving lindane have been conducted to evaluate its efficacy and safety in treating scabies and other parasitic infestations.

Efficacy and Safety

A notable study compared the therapeutic efficacy and safety of ivermectin and lindane in treating scabies. The study involved 53 patients randomly assigned to receive either a single oral dose of ivermectin or a single dose of 1% lindane topical solution. The results showed that both treatments had statistically equivalent therapeutic efficacy by day 29, with 95% of patients in the ivermectin group and 96% in the lindane group achieving healing of their scabies[1].

Treatment Protocol

Patients treated with lindane applied a 1% lindane topical solution over their entire body, from the neck to the toes, and kept it on for 8 hours. Bed clothes and personal clothes were washed with warm water or kept in polyethylene bags for 48 hours before washing. Patients who did not achieve a clinical cure after 15 days repeated the treatment[1].

Dropout and Severity

The study noted that slightly more patients dropped out of the ivermectin group than the lindane group. Patients who required a second dose had more severe forms of scabies, indicating that the severity of the condition could influence the need for repeated treatment[1].

Market Analysis

Global Market Size and Growth

The global lindane market has been analyzed in various reports to understand its current status and future trends. As of 2021, the global lindane market size was valued at several million dollars, with a projected growth rate from 2022 to 2028. The market is expected to reach a significant value by the end of 2028, driven by various factors including demand from end-use sectors and geographical regions[2][5].

Market Segmentation

The lindane market is segmented by product type, end-use/application, and geography. Key regions include North America, South America, Asia & Pacific, Europe, and the Middle East & Africa. The report also includes company profiles, product specifications, capacity, production value, and market shares for key vendors[2].

Key Players and Competitive Landscape

The market report identifies key players in the lindane industry, including their company profiles, main business information, SWOT analysis, sales, revenue, price, and gross margin. The competitive landscape analysis helps in understanding the market dynamics and growth opportunities[2].

Market Drivers and Constraints

Drivers

  • Demand from End-Use Sectors: Lindane is used in various applications, including pharmaceuticals and pesticides. The increasing demand from these sectors drives the market growth.
  • Geographical Expansion: The market is expanding in regions such as Asia & Pacific, driven by growing industrial and agricultural activities[2][5].

Constraints

  • Regulatory Issues: Lindane is a highly regulated substance due to its potential environmental and health hazards. Strict regulations can limit its market growth.
  • Alternative Treatments: The availability of alternative treatments, such as ivermectin, can also impact the demand for lindane[1][5].

Future Projections

Market Forecast

The global lindane market is expected to grow at a moderate CAGR from 2022 to 2028. The forecast indicates that the market will reach a significant value by the end of 2028, driven by increasing demand and technological advancements in manufacturing and application methods[2][5].

Technological Advancements

While lindane itself is not undergoing significant technological changes, advancements in related fields such as pharmaceutical research and development can influence its market. For instance, the integration of AI and machine learning in clinical trials, as seen in other pharmaceutical areas, could indirectly benefit the lindane market by improving overall treatment efficacy and safety assessments[3].

Conclusion

Lindane remains a relevant treatment option for scabies and other parasitic infestations, despite the availability of alternative treatments. Clinical trials have demonstrated its efficacy and safety, although regulatory and environmental concerns continue to be significant factors. The market analysis indicates a steady growth trajectory driven by demand from various sectors and geographical regions.

Key Takeaways

  • Efficacy and Safety: Lindane is as effective as ivermectin in treating scabies, with high healing rates observed in clinical trials.
  • Market Growth: The global lindane market is expected to grow at a moderate CAGR from 2022 to 2028.
  • Market Segmentation: The market is segmented by product type, end-use/application, and geography.
  • Regulatory Constraints: Strict regulations due to environmental and health hazards can limit market growth.
  • Technological Advancements: Indirect benefits from advancements in pharmaceutical research and development can influence the lindane market.

FAQs

What is the current status of clinical trials involving lindane?

Clinical trials have shown that lindane is as effective as ivermectin in treating scabies, with high healing rates observed by day 29[1].

What are the key drivers of the global lindane market?

The key drivers include demand from end-use sectors such as pharmaceuticals and pesticides, and geographical expansion, particularly in the Asia & Pacific region[2][5].

What are the main constraints affecting the lindane market?

The main constraints include regulatory issues due to environmental and health hazards, and the availability of alternative treatments such as ivermectin[1][5].

How is the lindane market segmented?

The market is segmented by product type, end-use/application, and geography, including key regions such as North America, South America, Asia & Pacific, Europe, and the Middle East & Africa[2].

What is the projected growth rate of the global lindane market?

The global lindane market is expected to grow at a moderate CAGR from 2022 to 2028, reaching a significant value by the end of 2028[2][5].

Are there any technological advancements influencing the lindane market?

While lindane itself is not undergoing significant technological changes, advancements in related fields such as pharmaceutical research and development can indirectly benefit the market by improving overall treatment efficacy and safety assessments[3].

Sources

  1. JAMA Dermatology: "Equivalent Therapeutic Efficacy and Safety of Ivermectin and Lindane in the Treatment of Scabies."
  2. 24 Market Reports: "Global Lindane Market Report 2022 - Market Size, Share, Price, Trend and Forecast."
  3. Collective Minds Research: "Clinical Trial Imaging Market: Size, Growth Analysis & Forecast 2024-2029."
  4. ClinicalTrials.gov: "Clinical Trials - Lindane."
  5. Research and Markets: "Lindane (CAS 58-89-9) Global Market Research Report 2024."

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.